Arkuda Therapeutics Announces Option Exercise and Asset Purchase
Arkuda Therapeutics Announces Option Exercise and Asset Purchase
Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.) were investors in the company. Johnson & Johnson has exercised its option to acquire Arkuda's portfolio of lysosomal function enhancers in exchange for an upfront payment and opportunity for additional milestone payments.
強生已行使其收購Arkuda的溶酶體功能增強劑組合的選項，並支付一筆預付款以及額外里程碑付款的機會。
WATERTOWN, Mass., Jan. 9, 2025 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal biology and neuronal health to develop medicines that change the trajectory of neurodegenerative disease, today announced that Johnson & Johnson* has executed its exclusive option to purchase Arkuda's portfolio of lysosomal function enhancers.
馬薩諸塞州沃特敦，2025年1月9日 /美通社/ -- Arkuda Therapeutics是一家生物技術公司，運用溶酶體生物學與神經健康交叉領域的新見解，開發改變神經退行性疾病軌跡的藥物，今天宣佈強生*已經執行其獨佔選項，購買Arkuda的溶酶體功能增強劑組合。
As part of this agreement, Arkuda receives an upfront payment and opportunity for additional payments for the achievement of certain development and commercial milestones.
根據這項協議，Arkuda將獲得一筆預付款，並有機會因實現某些開發和商業里程碑而獲得額外付款。
Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.) were investors in the company.
強生（通過其企業創投組織強生創新 – JJDC, Inc.）是該公司的投資者。
"Arkuda's continuing leadership in the area of lysosomal biology in neurodegeneration over the past several years has culminated in the identification of promising small molecule enhancers of lysosomal function which modulate lysosomal biology beneficially," said Gerhard Koenig, Ph.D., Founder, President and CEO, adding, "With its industry-leading capabilities in the development of drugs for neurodegenerative diseases like Alzheimer's Disease and Parkinson's Disease, we believe that Johnson & Johnson is well-positioned to advance these molecules toward human clinical studies."
「Arkuda在過去幾年中在神經退行性疾病的溶酶體生物學領域的持續領導地位 culminated於識別出有前景的溶酶體功能小分子增強劑，這些增強劑有益地調節溶酶體生物學，」創始人、總裁兼首席執行官Gerhard Koenig博士表示，並補充道，「憑藉其在開發阿爾茨海默病和帕金森病等神經退行性疾病藥物方面的行業領先能力，我們相信強生能夠將這些分子推進到臨牀研究中。」
* On February 27, 2024 Arkuda announced that it entered into an option and asset purchase agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.
* 2024年2月27日，Arkuda宣佈與強生子公司雅培製藥公司達成了一項選項和資產購買協議。
About Arkuda Therapeutics
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. The company is exploring the therapeutic potential of its lysosomal function enhancers in neurodegenerative diseases where genetic links to dysfunction in progranulin and lysosomal biology have been established, including Frontotemporal Dementia, Alzheimer's Disease and Parkinson's Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, abrdn plc, Mission BioCapital, Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.) and Eli Lilly and Company. To learn more visit .
關於Arkuda Therapeutics
Arkuda Therapeutics是一家生物技術公司，運用對溶酶體生物學的見解推動藥物開發，以改變神經退行性疾病的軌跡。該公司正在探索其溶酶體功能增強劑在神經退行性疾病中的治療潛力，這些疾病與 progranulin 和溶酶體生物學功能障礙存在已建立的遺傳聯繫， 包括額顳葉癡呆、阿爾茨海默病和帕金森病。Arkuda得到了包括Atlas Venture、Cormorant 資產管理、輝瑞創投、abrdn plc、Mission BioCapital、強生（通過其企業創投組織強生創新 – JJDC, Inc.）和禮來公司的領先投資者的支持。欲了解更多信息，請訪問 .
Media Contact:
Amanda Sellers
Deerfield Group
[email protected]
媒體聯繫人：
阿曼達·塞勒斯
迪爾菲爾德集團
[email protected]
SOURCE Arkuda Therapeutics
來源 阿庫達生物科技
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎？
譯文內容由第三人軟體翻譯。
